This article is more than 5 years old. Information may no longer be current.

Additional vaccine approved for 2009 influenza A (H1N1)

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A fifth vaccine will be available to protect adults aged 18 and older from 2009 influenza A (H1N1), after the FDA approved the product earlier this week.

The monovalent vaccine (ID Biomedical Corp.) was produced using the same egg-based manufacturing process as is used for seasonal influenza vaccine, and will be available in multidose vials. The formulation contains the preservative thimerosal.

Officials expect mild adverse events similar to those that occur with other seasonal influenza and H1N1 vaccines, which include injection site soreness, mild fever, body aches and fatigue for a few days after the vaccine is administered. The FDA encourages physicians to report unexpected rare serious adverse events, and will collaborate with the U.S. Department of Health and Human Services and the CDC to enhance safety monitoring during the H1N1 vaccination campaign.